Mamedica has announced a £4.5 million funding round led by Casa Verde, the US-based cannabis-focused venture capital firm.
Launched in 2022 by CEO and founder Jon Robson, Mamedica provides specialist treatment for chronic and neurological conditions including pain, anxiety, ADHD and depression. Its digital model enables remote consultations with specialist clinicians, with medication delivered nationwide by secure next-day courier. Since inception, Mamedica has treated over 10,000 patients, with approximately 7,500 actively under care and around 10% month-on-month growth in initial consultations. The company recorded 1,250% patient growth in 2023 and 154% in 2024 and expects to double patient numbers annually as the UK medical cannabis industry approaches £1bn in annual sales by the end of 2028.
"We're excited to partner with Mamedica as the UK cannabis market enters a period of rapid growth," said Karan Wadhera, Managing Partner at Casa Verde. "Mamedica's digital-first, patient-centric model sets the standard for care in the UK and offers a blueprint for broader European expansion."
"This funding marks a pivotal milestone in Mamedica's mission to transform patient care in the UK," said Jon Robson, CEO and founder of Mamedica. "The backing of Casa Verde and our private investors validates our approach and enables us to accelerate access to high-quality, regulated treatment."
For more information:
Mamedica
Email: [email protected]
https://mamedica.co.uk/
